MARKET

BNTC

BNTC

Benitec Biopharm
NASDAQ
11.56
-0.04
-0.34%
Pre Market: 11.57 +0.01 +0.09% 07:59 05/29 EDT
OPEN
11.56
PREV CLOSE
11.60
HIGH
11.72
LOW
11.23
VOLUME
4.80K
TURNOVER
0
52 WEEK HIGH
17.15
52 WEEK LOW
9.85
MARKET CAP
397.14M
P/E (TTM)
-10.4389
1D
5D
1M
3M
1Y
5Y
1D
Benitec Biopharma files Form 3 for director David Matthew Friedman
PUBT · 15h ago
Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained
TipRanks · 3d ago
Weekly Report: what happened at BNTC last week (0518-0522)?
Weekly Report · 4d ago
Weekly Report: what happened at BNTC last week (0511-0515)?
Weekly Report · 05/18 10:06
Benitec Biopharma posts BB-301 gene therapy update for OPMD-related dysphagia
PUBT · 05/16 01:22
Leerink Partners Keeps Their Buy Rating on Benitec Biopharma (BNTC)
TipRanks · 05/15 15:25
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
TipRanks · 05/15 02:55
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate
Benzinga · 05/14 12:41
More
About BNTC
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Webull offers Benitec Biopharma Inc stock information, including NASDAQ: BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.